Drug · CHEMBL708
ZIPRASIDONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ZIPRASIDONE. Drugs and targets, record CHEMBL708. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL708
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
| HTR2C | 5-hydroxytryptamine receptor 2C | Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3358 |
Source ChEMBL
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials124
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00312494 | 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects | Phase 3 | 680 | 2010-01-22 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00254202 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia | Phase 3 | 593 | 2024-12-13 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00280566 | Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed) | Phase 3 | 584 | 2009-12-14 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT01211522 | The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study | Phase 3 | 566 | 2019-08-20 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00141271 | A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression | Phase 3 | 536 | 2009-03-24 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00633399 | Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs | Phase 2 | 458 | 2014-07-03 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00282464 | A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression. | Phase 3 | 392 | 2009-06-02 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00723606 | A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation | Phase 3 | 376 | 2010-08-25 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00330863 | Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy | Phase 4 | 357 | 2018-07-10 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00139737 | Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia | Phase 3 | 344 | 2010-07-14 | ziprasidone | Its name | ClinicalTrials.gov |
1 to 10 of 124
See all 124 trialsComparisons in its trials39
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ziprasidone vs Haloperidol: serious adverse events | 0 of 189 | 0 of 187 | 376 | NCT00723606 | Trial comparisons |
| Injectable vs Oral: Number of Patients Discontinuing From the Study | 81 of 153 | 80 of 152 | 305 | NCT00330863 | Trial comparisons |
| Injectable vs Oral: serious adverse events | 61 of 146 | 48 of 150 | 296 | NCT00330863 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 147 | 6 of 147 | 294 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Response: Number of Subjects With Total MADRS Score Reduction ≥ 50 Percent From Baseline at Week 6 | 62 of 145 | 65 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6 | 66 of 145 | 69 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Remission: Number of Subjects With Total MADRS Score ≤ 12 at Week 6 | 48 of 145 | 54 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 9 of 193 | 1 of 90 | 283 | NCT00257192 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 6 of 149 | 7 of 88 | 237 | NCT00257166 | Trial comparisons |
| Stay vs Switch: serious adverse events | 0 of 102 | 2 of 117 | 219 | NCT00044655 | Trial comparisons |
1 to 10 of 39
See all 39 comparisons in its trialsPapers from its trials131
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 3 | 1 | ConductCognition |
| Stroop Color-Word Test | 2 | 0 | ConductCognition |
| Tower Planning | 2 | 0 | ConductCognition |
| Trail Making Test A | 2 | 0 | ConductCognition |
| Trail Making Test B | 2 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Letter-Number Sequencing Task | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL708
GET https://conductscience.org/api/drugs/v1/CHEMBL708/diseases?page=2